[Commentary] On October 20, the State Information Office held a press conference.

According to Peng Huagang, Secretary-General of the State-owned Assets Supervision and Administration Commission and spokesperson of the State-owned Assets Supervision and Administration Commission, from the perspective of the operation of the first three quarters, the vast majority of central enterprises have continued the positive development trend of continuous improvement in production and operation and rapid recovery of economic benefits.

The economic efficiency of central enterprises has improved significantly, and the operating income of the third quarter turned from negative to positive.

　　[Concurrent] Peng Huagang, Spokesperson of SASAC

　　Operating income in the third quarter turned from negative to positive, maintaining double-digit growth for three consecutive months.

The unfavorable situation in the first half of the year was basically reversed, and production and operation returned to normal tracks.

The production and sales of key products related to the national economy, people's livelihood, and national security, such as coal, electricity, oil, and transportation, have stabilized, approaching or returning to normal levels.

Investment activities continued to accelerate.

Continuous improvement of operation quality.

In the first three quarters, the profit margin of central enterprises' revenue remained above 7%, and reached 9.5% in September, the best level in a decade.

The net cash flow from operating activities exceeded 400 billion yuan, which has returned to normal levels.

　　[Commentary] At the meeting, a reporter asked, what was the investment situation of central enterprises in the first three quarters?

What are the characteristics?

Peng Huagang said that in 2020, the investment scale of central enterprises will continue to increase and the investment structure will continue to be optimized.

Increased investment in the "two new and one heavy" areas has strengthened the stamina for industrial upgrading and structural adjustment.

　　[Concurrent] Peng Huagang, Spokesperson of SASAC

　　In the first three quarters, central enterprises completed fixed asset investment, excluding real estate investment, totaling 1.8 trillion (yuan), an increase of 11.3% year-on-year.

In September, we completed a fixed asset investment of 339.2 billion yuan, an increase of 66.7% from the previous month.

Manufacturing investment (including equity investment) increased by 9% year-on-year, investment in strategic emerging industries increased by 37% year-on-year, and investment accounted for more than 20%, which was the best level in history.

In the first three quarters, central enterprises completed more than 250 billion yuan (yuan) in new infrastructure investment, mainly in 5G, smart energy, industrial Internet and other fields.

At present, 600,000 5G base stations have been built nationwide.

　　[Explanation] Peng Huagang said that in the next step, the SASAC will continue to guide enterprises to do the tasks of "six stability" and "six guarantees", implement the annual investment plan in a stable and orderly manner, continue to increase investment, and make better use of investment An important supporting role for economic growth.

　　At the meeting, in response to questions about the cooperation between China's central enterprises and other countries and international organizations in the development of new crown vaccines after China and the Global Vaccine Alliance signed an agreement and decided to join the "New Crown Vaccine Implementation Plan" on October 8, Peng Huagang Means:

　　[Concurrent] Peng Huagang, Spokesperson of SASAC

　　At present, the two vaccines of China Biological Group have conducted phase III clinical trials internationally. There are already 50,000 samples in 10 countries, and these 50,000 people involve people of 125 nationalities.

Looking at the current situation, generally speaking, the progress of Phase III clinical trials is very smooth, and the SASAC is also organizing China National Biological Group to actively promote Phase III clinical trials and collect data as soon as possible.

In addition, we are also actively studying the expansion of vaccine production capacity, and strive to play a greater role in our next international cooperation.

　　Reporter Liu Xuanting reports from Beijing

Editor in charge: [Li Yuxin]